DE25179059T1 - Flüssige pharmazeutische zusammensetzung von adalimumab - Google Patents

Flüssige pharmazeutische zusammensetzung von adalimumab

Info

Publication number
DE25179059T1
DE25179059T1 DE25179059.8T DE25179059T DE25179059T1 DE 25179059 T1 DE25179059 T1 DE 25179059T1 DE 25179059 T DE25179059 T DE 25179059T DE 25179059 T1 DE25179059 T1 DE 25179059T1
Authority
DE
Germany
Prior art keywords
histidine
pharmaceutical composition
liquid pharmaceutical
zwitterionic
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE25179059.8T
Other languages
German (de)
English (en)
Inventor
Gianluca Rinaldi
Silvia Fratarcangeli
Alessandra Del Rio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fresenius Kabi Deutschland GmbH
Original Assignee
Fresenius Kabi Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50774705&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE25179059(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fresenius Kabi Deutschland GmbH filed Critical Fresenius Kabi Deutschland GmbH
Publication of DE25179059T1 publication Critical patent/DE25179059T1/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE25179059.8T 2014-05-23 2015-05-15 Flüssige pharmazeutische zusammensetzung von adalimumab Pending DE25179059T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14169754 2014-05-23
EP14169754.0A EP2946766B1 (en) 2014-05-23 2014-05-23 Liquid pharmaceutical composition
EP25179059.8A EP4585614A3 (en) 2014-05-23 2015-05-15 Liquid pharmaceutical composition of adalimumab

Publications (1)

Publication Number Publication Date
DE25179059T1 true DE25179059T1 (de) 2025-08-28

Family

ID=50774705

Family Applications (2)

Application Number Title Priority Date Filing Date
DE25179059.8T Pending DE25179059T1 (de) 2014-05-23 2015-05-15 Flüssige pharmazeutische zusammensetzung von adalimumab
DE23189888.3T Pending DE23189888T1 (de) 2014-05-23 2015-05-15 Flüssige pharmazeutische zusammensetzung von adalimumab

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE23189888.3T Pending DE23189888T1 (de) 2014-05-23 2015-05-15 Flüssige pharmazeutische zusammensetzung von adalimumab

Country Status (21)

Country Link
US (5) US10493152B2 (cg-RX-API-DMAC7.html)
EP (6) EP2946766B1 (cg-RX-API-DMAC7.html)
JP (3) JP2017516847A (cg-RX-API-DMAC7.html)
CN (2) CN108785670A (cg-RX-API-DMAC7.html)
AU (4) AU2015263246B2 (cg-RX-API-DMAC7.html)
CA (2) CA2947487C (cg-RX-API-DMAC7.html)
CY (1) CY1120488T1 (cg-RX-API-DMAC7.html)
DE (2) DE25179059T1 (cg-RX-API-DMAC7.html)
DK (3) DK3148510T3 (cg-RX-API-DMAC7.html)
ES (4) ES2572919T3 (cg-RX-API-DMAC7.html)
HK (1) HK1257026A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20181226T1 (cg-RX-API-DMAC7.html)
HU (1) HUE040097T2 (cg-RX-API-DMAC7.html)
IL (1) IL249117B2 (cg-RX-API-DMAC7.html)
LT (1) LT3148510T (cg-RX-API-DMAC7.html)
PL (1) PL3148510T3 (cg-RX-API-DMAC7.html)
PT (1) PT3148510T (cg-RX-API-DMAC7.html)
RS (1) RS57772B1 (cg-RX-API-DMAC7.html)
SI (1) SI3148510T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201800413T1 (cg-RX-API-DMAC7.html)
WO (1) WO2015177058A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2946765B1 (en) 2014-05-23 2016-08-31 Ares Trading S.A. Liquid pharmaceutical composition
ES2607489T3 (es) * 2014-05-23 2017-03-31 Ares Trading S.A. Composición farmacéutica líquida
EP2946766B1 (en) 2014-05-23 2016-03-02 Ares Trading S.A. Liquid pharmaceutical composition
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
EP3459527B1 (en) * 2017-09-20 2022-11-23 Tillotts Pharma Ag Method for preparing a solid dosage form comprising antibodies by wet granulation, extrusion and spheronization
MX421763B (es) * 2018-03-29 2025-03-14 Airway Therapeutics Inc Metodos y composiciones que comprenden proteina d tensoactiva (sp-d)
KR102731267B1 (ko) 2018-03-29 2024-11-18 에어웨이 테라퓨틱스, 아이엔씨. 계면활성제 단백질 d (sp-d) 올리고머의 특성화를 위한 시스템 및 방법
WO2020138517A1 (ko) * 2018-12-24 2020-07-02 삼성바이오에피스 주식회사 항-TNFα 항체를 포함하는 약제학적 조성물
WO2020145789A1 (ko) * 2019-01-11 2020-07-16 삼성바이오에피스 주식회사 항체를 포함하는 약학적 조성물, 이를 포함하는 디바이스, 및 이의 용도
US20230203147A1 (en) * 2019-03-18 2023-06-29 Alvotech Hf Aqueous formulations of tnf-alpha antibodies in high concentrations
CN115429751B (zh) * 2022-09-21 2023-11-17 景泽生物医药(合肥)股份有限公司 一种人重组卵泡刺激素注射剂及其制备方法
WO2025038671A2 (en) * 2023-08-15 2025-02-20 Amgen Inc. Acidic buffered intravenous solution stabilizers for use in methods of treatment

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6388197A (ja) 1986-09-30 1988-04-19 Tosoh Corp モノクロナル抗体の安定化方法
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
WO1997029131A1 (en) 1996-02-09 1997-08-14 Basf Aktiengesellschaft HUMAN ANTIBODIES THAT BIND HUMAN TNF$g(a)
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US5900404A (en) 1997-08-15 1999-05-04 Amgen Inc. Chemical modification of proteins to improve biocompatibility and bioactivity
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
JP4869064B2 (ja) 2003-04-04 2012-02-01 ジェネンテック， インコーポレイテッド 高濃度抗体及びタンパク質製剤
WO2005072772A1 (en) 2004-01-30 2005-08-11 Suomen Punainen Risti Veripalvelu Pharmaceutical compositions
CN101721701A (zh) 2004-07-23 2010-06-09 健泰科生物技术公司 抗体或其片段的结晶
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
DK2620450T3 (en) 2005-03-08 2019-02-04 Pfizer Prod Inc Antibody Compositions against CTLA-4
ES2424042T3 (es) 2005-06-07 2013-09-26 Esbatech - A Novartis Company Llc Anticuerpos estables y solubles que inhiben TNF±
TW200938221A (en) 2007-11-30 2009-09-16 Abbott Lab Protein formulations and methods of making same
US8080518B2 (en) 2007-12-05 2011-12-20 Arbor Vita Corporation Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
KR101593285B1 (ko) 2008-10-29 2016-02-11 아블린쓰 엔.브이. 단일 도메인 항원 결합 분자의 제형
JP2012509270A (ja) 2008-11-17 2012-04-19 ジェネンテック， インコーポレイテッド 生理的条件下での高分子の凝集を低減するための方法及び製剤
CN104490767A (zh) 2009-05-04 2015-04-08 艾伯维生物技术有限公司 人抗TNF-α抗体的稳定高蛋白质浓度制剂
WO2011104381A2 (en) * 2010-02-26 2011-09-01 Novo Nordisk A/S Stable antibody containing compositions
JP5937523B2 (ja) 2010-03-01 2016-06-22 サイトダイン インコーポレイテッドＣｙｔｏＤｙｎ， Ｉｎｃ． 濃縮されたタンパク質製剤およびその使用
US20110223208A1 (en) 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
PL2550018T3 (pl) 2010-03-22 2019-08-30 F.Hoffmann-La Roche Ag Kompozycje i sposoby użyteczne do stabilizowania preparatów zawierających białko
EP2399604A1 (en) 2010-06-25 2011-12-28 F. Hoffmann-La Roche AG Novel antibody formulation
TWI606840B (zh) 2010-11-11 2017-12-01 艾伯維生物技術有限責任公司 具有增進高濃度之抗-ＴＮＦα抗體之液體調配物
EP2471554A1 (en) 2010-12-28 2012-07-04 Hexal AG Pharmaceutical formulation comprising a biopharmaceutical drug
EA026226B1 (ru) 2011-07-01 2017-03-31 Байоджен Айдек Ма Инк. Не содержащие аргинина композиции слитого fc-полипептида и способы их применения
GB201112429D0 (en) 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding
WO2013164837A1 (en) 2012-03-07 2013-11-07 Cadila Healthcare Limited Pharmaceutical formulations of tnf-alpha antibodies
EP2863951A1 (en) * 2012-06-12 2015-04-29 Boehringer Ingelheim International GmbH Pharmaceutical formulation for a therapeutic antibody
CN104768576A (zh) 2012-09-07 2015-07-08 科荣生生物科学公司 稳定的阿达木单抗水性制剂
RU2015119547A (ru) 2012-10-25 2016-12-20 МЕДИММЬЮН, ЭлЭлСи Стабильный низковязкий состав с антителом
EP2727602A1 (en) 2012-10-31 2014-05-07 Takeda GmbH Method for preparation of a high concentration liquid formulation of an antibody
AR093297A1 (es) * 2012-10-31 2015-05-27 Amgen Res Munich Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
US9833410B2 (en) 2012-10-31 2017-12-05 Takeda Gmbh Lyophilized formulation comprising GM-CSF neutralizing compound
CN105431453A (zh) 2012-11-01 2016-03-23 艾伯维公司 稳定的双重可变结构域免疫球蛋白制剂
CN104707146B (zh) 2013-12-16 2019-04-16 浙江海正药业股份有限公司 一种含有阿达木单抗的药物组合物
IN2014MU00610A (cg-RX-API-DMAC7.html) 2014-02-21 2015-09-25 Tata Motors Ltd
WO2015151115A1 (en) 2014-04-02 2015-10-08 Intas Pharmaceuticals Limited Liquid pharmaceutical composition of adalimumab
EP2946766B1 (en) 2014-05-23 2016-03-02 Ares Trading S.A. Liquid pharmaceutical composition
ES2607489T3 (es) 2014-05-23 2017-03-31 Ares Trading S.A. Composición farmacéutica líquida
EP2946765B1 (en) 2014-05-23 2016-08-31 Ares Trading S.A. Liquid pharmaceutical composition
WO2017136433A1 (en) * 2016-02-03 2017-08-10 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
EP3569224B1 (en) 2017-01-11 2022-12-14 Celltrion Inc. Stable liquid formula
WO2021182874A1 (ko) 2020-03-13 2021-09-16 삼성바이오에피스 주식회사 안정성이 증진된 액상 약제학적 조성물

Also Published As

Publication number Publication date
ES2955316T3 (es) 2023-11-30
JP6962984B2 (ja) 2021-11-05
ES2683194T3 (es) 2018-09-25
EP2946766B1 (en) 2016-03-02
AU2022203863A1 (en) 2022-06-23
DE23189888T1 (de) 2024-03-21
EP4249060A3 (en) 2024-01-03
CA2947487A1 (en) 2015-11-26
US10772961B2 (en) 2020-09-15
DK201800070Y8 (da) 2019-07-09
PL3148510T3 (pl) 2018-11-30
US11752209B2 (en) 2023-09-12
EP4585614A2 (en) 2025-07-16
EP4585614A3 (en) 2025-10-29
EP3659582A1 (en) 2020-06-03
CA3050875A1 (en) 2015-11-26
AU2020201090A1 (en) 2020-03-05
AU2018222887A1 (en) 2018-09-13
DK3148510T3 (en) 2018-07-16
DK201800070Y4 (da) 2018-12-13
HRP20181226T1 (hr) 2018-10-19
ES2928738T3 (es) 2022-11-22
JP2017516847A (ja) 2017-06-22
ES2572919T3 (es) 2016-06-03
EP4249060A2 (en) 2023-09-27
WO2015177058A1 (en) 2015-11-26
IL249117A0 (en) 2017-01-31
AU2015263246B2 (en) 2018-06-21
EP3148510B1 (en) 2018-06-27
IL249117B2 (en) 2024-11-01
US11752208B2 (en) 2023-09-12
AU2020201090B2 (en) 2022-03-10
JP2020033361A (ja) 2020-03-05
EP3403646A1 (en) 2018-11-21
SMT201800413T1 (it) 2018-11-09
US10493152B2 (en) 2019-12-03
US12109267B2 (en) 2024-10-08
AU2018222887B2 (en) 2020-02-27
HUE040097T2 (hu) 2019-02-28
CY1120488T1 (el) 2019-07-10
PT3148510T (pt) 2018-09-28
EP3148510A1 (en) 2017-04-05
DK201800071Y4 (da) 2018-12-13
DK201800070U1 (da) 2018-09-18
EP3403646B1 (en) 2022-09-28
SI3148510T1 (sl) 2018-10-30
EP3659582B1 (en) 2023-08-16
IL249117B1 (en) 2024-07-01
US20210023215A1 (en) 2021-01-28
CN106659781A (zh) 2017-05-10
AU2015263246A1 (en) 2016-11-17
US20230338527A1 (en) 2023-10-26
DK201800071U1 (da) 2018-12-05
US20170189527A1 (en) 2017-07-06
US20230061801A1 (en) 2023-03-02
CA2947487C (en) 2019-09-24
HK1257026A1 (zh) 2019-10-11
LT3148510T (lt) 2018-10-10
RS57772B1 (sr) 2018-12-31
CN108785670A (zh) 2018-11-13
JP2022003091A (ja) 2022-01-11
EP2946766A1 (en) 2015-11-25
US20200085948A1 (en) 2020-03-19

Similar Documents

Publication Publication Date Title
DE25179059T1 (de) Flüssige pharmazeutische zusammensetzung von adalimumab
MX2023008626A (es) Proteinas klotho recombinantes terapeuticas y composiciones y metodos que involucran a las mismas.
US20250145717A1 (en) Anti-pdl1 antibody formulations
MX2025012669A (es) Proteinas klotho recombinantes novedosas y composiciones y metodos que involucran a las mismas
US7691379B2 (en) Anti-IL-9 antibody formulations
HRP20191966T4 (hr) Stabilizirani neproteinski klostridijalni pripravci toksina
AR109494A1 (es) Formulaciones de anticuerpos inhibidores de masp-2 de baja viscosidad y altamente concentradas, kits, y métodos
AR121856A1 (es) Inmunoconjugados
DE18190279T1 (de) Pharmazeutische anti-tnf-alpha-antikörperformulierung
NZ739503A (en) A novel approach for treatment of cancer using immunomodulation
JP2017510567A5 (cg-RX-API-DMAC7.html)
HRP20200881T1 (hr) Antitijela koja vežu beta-klotho domenu 2 i postupci njihove uporabe
HRP20201268T1 (hr) Stabilne formulacije koje sadrže anti-pcsk9 antitijela
AR102096A1 (es) Proceso para elaborar acetato de glatiramer
IL309340A (en) Dosing regimen for missing doses of paliperidone long-acting injectable esters
RU2015119603A (ru) Стабильная фармацевтическая композиция на основе слитого белка tnfr:fc
RU2019102943A (ru) Составы на основе антитела
US20090053238A1 (en) Stabilized High Concentration Anti-Integrin alphavbeta3 Antibody Formulations
Nakamura CellSaic, a cell aggregate-like technology using recombinant peptide pieces for MSC transplantation
US20190284282A1 (en) Stable pharmaceutical composition
FI3390448T3 (fi) Intravesikaalinen hoito virtsarakon syöpää varten
JP2018538308A5 (cg-RX-API-DMAC7.html)
JP2023532326A (ja) 抗ｆｃｒｎ抗体のための製剤
WO2023278821A3 (en) Superconcentrated formulations of bioactive agents
RU2020119597A (ru) Композиция для лечения пациента с респираторным заболеванием, обусловленным хроническим воспалением, способ получения и применение указанной композиции